報價延遲最少15分鐘:2026/04/21 20:02 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
26.95 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.55/-0.64
|
|
企業價值
448.28M
|
| 資產負債 |
|
每股賬面淨值
13.03
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
72.30M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points.The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses. |
